UB

Urvashi Bhavik Jani

Active Director Director DIN 10710559
DIN 10710559 First appointment Jul 2024 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2024
Shareholding value •••• Premium profile

About Urvashi Bhavik Jani

Data last updated:

Urvashi Bhavik Jani is a Director at Clineunoia Pharmaceuticals Private Limited (since 2024). The company operates in Pharma. Clineunoia Pharmaceuticals Private Limited reported revenue of ₹81,000 (FY 2025).

DIN 10710559
Primary Designation Director
Industry Pharma
First Appointment 18 Jul 2024
Oldest Company Age 2 yrs
Largest company Clineunoia Pharmaceuticals Private Limited · ₹81,000 (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director18 Jul 20242024₹81,000 (FY 2025)Active

Board colleagues of Urvashi Bhavik Jani

Directorship timeline

Open interactive timeline →
Clineunoia Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Urvashi Bhavik Jani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Urvashi Bhavik Jani

Urvashi Bhavik Jani currently holds 1 directorship: Clineunoia Pharmaceuticals Private Limited (Director, since 18 Jul 2024, revenue ₹81,000 (FY 2025)).

Urvashi Bhavik Jani was first appointed on 18 Jul 2024 as Director at Clineunoia Pharmaceuticals Private Limited.

The current boards of Urvashi Bhavik Jani's companies include Minaben Jashvantbhai Raval (Clineunoia Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available